Logo-ijhpm
Int J Health Policy Manag. 2018;7(2): 120-136. doi: 10.15171/ijhpm.2017.47
PMID: 29524936        PMCID: PMC5819372

Original Article

Measuring the Benefits of Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study of Two Preventive Interventions

Federico Augustovski 1 * , Lisandro D. Colantonio 2, Julieta Galante 3, Ariel Bardach 1, Joaquín E. Caporale 1, Víctor Zárate 4, Ling Hsiang Chuang 5, Andres Pichon Riviere 1, Paul Kind 6

Cited by CrossRef:

1- Niyibitegeka F, Thavorncharoensap M, Riewpaiboon A, Youngkong S. Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi. Appl Health Econ Health Policy. 2022;20(5):707 [Crossref]
2- Pinto dos Santos J, Bernardes de Oliveira S. A Financial Theory Perspective of the Metrics Employed to Measure Value in the “Value in Healthcare” Methodologies. Port J Public Health. 2020;38(3):176 [Crossref]
3- van der Vliet N, Suijkerbuijk A, de Blaeij A, de Wit G, van Gils P, Staatsen B, Maas R, Polder J. Ranking Preventive Interventions from Different Policy Domains: What Are the Most Cost-Effective Ways to Improve Public Health?. IJERPH. 2020;17(6):2160 [Crossref]
4- Karimian F. A commentary on: “Cost-effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery” (Int J Surg 2019; 70: 35–43). International Journal of Surgery. 2019;72:128 [Crossref]
5- Mauskopf J, Standaert B, Connolly M, Culyer A, Garrison L, Hutubessy R, Jit M, Pitman R, Revill P, Severens J. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health. 2018;21(10):1133 [Crossref]
6- Shaker M, Abrams E, Oppenheimer J, Singer A, Shaker M, Fleck D, Greenhawt M, Grove E. Estimation of Health and Economic Benefits of a Small Automatic External Defibrillator for Rapid Treatment of Sudden Cardiac Arrest (SMART): A Cost-Effectiveness Analysis. Front Cardiovasc Med. 2022;9 [Crossref]
7- Edoka I, Stacey N. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. 2020;35(5):546 [Crossref]
8- Tsuzuki S, Beutels P. The estimated disease burden of COVID-19 in Japan from 2020 to 2021. Journal of Infection and Public Health. 2023;16(8):1236 [Crossref]
9- Lysholm S, Chaters G, Di Bari C, Hughes E, Huntington B, Rushton J, Thomas L. A framework for quantifying the multisectoral burden of animal disease to support decision making. Front Vet Sci. 2025;12 [Crossref]
10- Shaker M, Hsu Blatman K, Abrams E. Engaging patient partners in state-of-the-art allergy care. Annals of Allergy, Asthma & Immunology. 2020;125(3):252 [Crossref]
11- Yurekli A, Bilir N, Husain M, Chen S. Projecting burden of hypertension and its management in Turkey, 2015-2030. PLoS ONE. 2019;14(9):e0221556 [Crossref]
12- Addo R, Haas M, Goodall S. The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women. Value in Health Regional Issues. 2021;25:196 [Crossref]
13- Feng X, Kim D, Cohen J, Neumann P, Ollendorf D. Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter?. Int J Technol Assess Health Care. 2020;36(2):96 [Crossref]
14- Park B, Ock M, Jo M, Lee H, Lee E, Park B, Park H. Health gap for multimorbidity: comparison of models combining uniconditional health gap. Qual Life Res. 2020;29(9):2475 [Crossref]
15- Ilaiwy G, Keim-Malpass J, Tuppal R, Ritua A, Bassiag F, Thomas T. Cost effectiveness analysis of expanding tuberculosis preventive therapy to household contacts aged 5–14 years in the Philippines. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2025;39:100519 [Crossref]
16- Liu H, Dai W. An Empirical Study on the Benefits Equity of the Medical Security Policy: the China Health and Nutrition Survey (CHNS). IJERPH. 2020;17(4):1203 [Crossref]
17- Buchanan J, Altunkaya J, Van Kinh N, Van Vinh Chau N, Trieu Ly V, Thi Thanh Thuy P, Hai Vinh V, Thi Hong Hanh D, Thuy Hang N, Phuong Thuy T, van Doorn R, Thwaites G, Gray A, Le T. Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus–Infected Adults in Vietnam. 2021;8(7) [Crossref]
18- Lehnert T, Konnopka A, König H. Gesundheitsökonomische Aspekte von Übergewicht und Adipositas: Krankheitskosten und Kosteneffektivität am Beispiel von Werberegulierungen. Adipositas - Ursachen, Folgeerkrankungen, Therapie. 2022;16(02):76 [Crossref]
19- Sharma D, Aggarwal A, Bahuguna P, Prinja S. The Impact of Alternate Methodological and Structural Assumptions on Results of Cost-effectiveness Analysis: Empirical Evidence using Three Indian Economic Evaluations. 2024;68(1):9 [Crossref]
20- Zafarnejad R, Chen Q, Griffin P, Battaglia Y. Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic. PLoS ONE. 2024;19(3):e0299401 [Crossref]
21- Koshkina N. Assessing economic damage to the health care system caused by climate change (through the example of Moscow). Èkonomika i upravlenie. 2023;29(2):224 [Crossref]
22- Ochalek J, Lomas J. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics. 2020;42(1):44 [Crossref]
23- Lian J, McGhee S, So C, Chau J, Wong C, Wong W, Lam C. Long‐term cost‐effectiveness of a Patient Empowerment Programme for type 2 diabetes mellitus in primary care. Diabetes Obesity Metabolism. 2019;21(1):73 [Crossref]
24- Gesesew H, Mwanri L, Stephens J, Woldemichael K, Ward P. COVID/HIV Co-Infection: A Syndemic Perspective on What to Ask and How to Answer. Front Public Health. 2021;9 [Crossref]
25- Barr R. The challenges of delivering cost‐effective and affordable care to children with cancer in the developing world. Cancer. 2021;127(5):676 [Crossref]
26- Cardoso-Grilo T, Oliveira M, Barbosa-Póvoa A. Fostering long-term care planning in practice: extending objectives and advancing stochastic treatment within location-allocation modelling. European Journal of Operational Research. 2021;291(3):1041 [Crossref]
27- Guha C, O'Reilly C, Silva J, Howell M. Navigating Choices in Nephrology: The Role of Patient-Reported Outcomes and Preferences in Economic Evaluations and Decisions in Health Care. Seminars in Nephrology. 2024;44(3-4):151554 [Crossref]
28- Duan K, Rodriguez Garza F, Flores H, Palazuelos D, Maza J, Martinez-Juarez L, Elliott P, Moreno Lázaro E, Enriquez Rios N, Nigenda G, Palazuelos L, McBain R. Economic evaluation of a novel community-based diabetes care model in rural Mexico: a cost and cost-effectiveness study. BMJ Open. 2021;11(4):e046826 [Crossref]
29- Harris J, Ritchie C, Hanna G, McCain J, Ji Y. The Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries. Journal of Oral and Maxillofacial Surgery. 2021;79(6):1364 [Crossref]
30- Li X, Chen H, Lei X, Dou G, Chen Y, Chen L, Zhang Y, Zhao G, Zhong W. Cost‐effectiveness analysis of a community‐based colorectal cancer screening program in Shanghai, China. J of Digest Diseases. 2021;22(8):452 [Crossref]
31- Iino H, Hashiguchi M, Hori S, Fu S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review. PLoS ONE. 2022;17(4):e0266934 [Crossref]
32- Errigo I, Abbott B, Mendoza D, Mitchell L, Sayedi S, Glenn J, Kelly K, Beard J, Bratsman S, Carter T, Chaney R, Follett A, Freeman A, Frei R, Greenhalgh M, Holmes H, Howe P, Johnston J, Lange L, Martin R, Stacey A, Tran T, Wilson D. Human Health and Economic Costs of Air Pollution in Utah: An Expert Assessment. Atmosphere. 2020;11(11):1238 [Crossref]
33- Yin M, Gu Y, Shu J, Zhang B, Su M, Zhang L, Jiang Y, Qin G. Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study. Vaccine. 2023;41(40):5825 [Crossref]